Millennium Management
BDTX icon

Millennium Management’s Black Diamond Therapeutics BDTX Stock Holding History

Millennium Management’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-184,200
Closed -$801K – 5961
2024
Q3 		$801K Buy
+184,200
New +$1M ﹤0.01% 4445

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management's BDTX Position: Q1 2026 in Review

Millennium Management reduced its Black Diamond Therapeutics (BDTX) stake by 54% in Q1 2026, selling an estimated $384K and leaving 134,979 shares worth $288K. The position accounts for ﹤0.01% of the portfolio, ranked #5025.

Millennium Management first reported a position in BDTX in Q1 2020 and has held it in 24 quarters since. The position peaked at $5.55M in Q4 2020. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Millennium Management held 134,979 shares of Black Diamond Therapeutics worth $288K as of Q1 2026.
  • Millennium Management sold 161,577 Black Diamond Therapeutics shares in Q1 2026, an estimated $384K.
  • Black Diamond Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #5025 holding.
  • Millennium Management first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • Millennium Management's Black Diamond Therapeutics position peaked at $5.55M in Q4 2020.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.